Pharmaceutical Executive
Pharmaceutical Executive
Pharmaceutical Executive Podcast
Pharmaceutical Executive Daily: FDA Grants Accelerated Approval to Rybrevant Faspro
2 minutes Posted Nov 6, 2026 at 3:52 pm.
0:00
2:16
Download MP3
Show notes
Hims & Hers partners with Eli Lilly to sell Zepbound and Foundayo directly on its platform, Novo Nordisk terminates its research collaboration with Korro Bio, and the FDA grants accelerated approval to Johnson & Johnson’s Rybrevant Faspro in head and neck cancer.